Celgene

Celgene

Metrics Value

Environmental Fines (G4-EN29-a)

2014 = $ 0

Indirect greenhouse gas (GHG) emissions (Scope 2) (G4-EN16-a)

2014 = 14,939 tonnes CO2 equivalent

Greenhouse Gas (GHG) emissions intensity ratio (G4-EN18-a)

2014 = 5 : 1

Hazardous Waste Recycled (G4-EN23-a)

2014 = Unknown tonnes

Energy intensity (G4-EN5-a)

2014 = 82 : 1

Non-hazardous Waste Recycled (G4-EN-23-a)

2014 = Unknown tonnes

Fuel Consumption from Non-renewable sources (G4-EN3-a)

2014 = 168,118 Gigajoules

Fuel consumption from renewable sources (G4-EN3-b)

2014 = 9,592 Gigajoules

Non-Hazardous Waste (G4-EN23-a)

2014 = Unknown tonnes

Total water discharge (G4-EN22-a)

2014 = 321,969 m3

Volatile Organic Compounds (VOC) emissions (G4-EN21-a)

2014 = Unknown tonnes

Hazardous Waste Created (G4-EN23-a)

2014 = Unknown tonnes

Combined Scope 1, 2 and 3 Intensity

2013 = 343.92

Reduction of greenhouse gas (GHG) emissions (G4-EN19-a)

2014 = 1065 tonnes CO2 equivalent

Municipal Water Withdrawals (G4-EN8-a)

2014 = 390,356 m3

Reduction of Energy Consumption (G4-EN6-a)

2014 = 6,565 Gigajoules

Persistent organic pollutants (POP) (G4-EN21-a)

2014 = Unknown tonnes

NOx emissions (G4-EN21-a)

2014 = Unknown Tonnes

Hazardous air pollutant (HAP) emissions (G4-EN21-a)

2014 = Unknown tonnes

Scope 1 and 2 Intensity

2013 = 198.2
+Wikipedia
Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals.